| 2012 - 2014 | Preparing for tuberculosis vaccine efficacy trials: Identifying at-risk individuals for TB vaccine trials. | Harleen Grewal |
| 2012 - 2014 | Development of biodegradable nanobeads as vaccines against tuberculosis. | Gareth Griffiths |
| 2010 - 2014 | Vaccine development in Orientia tsutsugamushi infection | Pål Aukrust |
| 2010 - 2014 | Advancing Rotavirus Vaccine Development (ARVAC) - BBIL Phase 3 Study | John Boslego |
| 2010 - 2012 | 'Communicate to vaccinate': Building evidence for improving communication about childhood vaccinations in low- and middle-income | Simon Lewin |
| 2010 - 2013 | Vaccibodies for SIV: a step towards an HIV vaccine for humans. | Inger Øynebråten |
| 2010 - 2013 | Novel vaccine candidates against meningococcal disease | Tone Tønjum |
| 2010 - 2014 | Molecular control of T cell memory | Anne Spurkland |
| 2010 - 2013 | Health systems strengthening within vaccination programmes: an ethnographic study (HEALVAC) | Sidsel Roalkvam |
| 2010 - 2013 | Phase III rotavirus vaccine trials in India: Bilateral competence building | Tor Arne Strand |
| 2010 - 2013 | Development of a food-grade Lactobacillus-based oral vaccine delivery system | Vincent Eijsink |
| 2010 - 2013 | mVAC - Mobile innovations in recording child vaccination and health data in immunization registers | Thorkild Tylleskær |
| 2010 - 2013 | Studies of humoral and cell-mediated protective immune markers during Mycobacterium tuberculosis infection in human population | Gunnar Aksel Bjune |
| 2010 - 2013 | Biomarkers of mycobacterial infection and disease, and molecular characterization of mycobacteria from high TB-burden countries. | Ruth Stavrum |
| 2010 - 2013 | To what extent do user fees affect Hepatitis B vaccine coverage rates in China? | Knut Reidar Wangen |
| 2010 - 2015 | Target cell recognition by natural killer cells | Erik Dissen |
| 2010 - 2014 | IgA antibodies in saliva as a noninvasive readout for intestinal immune responses | Per Brandtzæg |
| 2010 - 2012 | Additional activities related to an ongoing project: Impact of the new vaccine MenAfriVac on carriage of serogroup A Neisseria m | Dominique A. Caugant |
| 2009 - 2012 | Development of novel vaccine candidates to prevent primary or reactivated tuberculosis | Harald G. Wiker |
| 2009 - 2013 | Mucosal vaccination against autoimmune disease | Roland Jonsson |
| 2009 - 2013 | Expression and evaluation of envelope domain III-based experimental tetravalent dengue vaccine using tobacco chloroplast express | Jihong Liu Clarke |
| 2009 - 2013 | Application of Open Source Licensing to Vaccine and Medicine Discovery and Development | Atle Fretheim |
| 2009 - 2013 | Improved vaccination responses and optional immunomodulating therapy by adjuvant administration of COX-2 inhibitor in HIV-infect | Dag Kvale |
| 2009 - 2010 | Development of a proposal on Norwegian engagement and collaborative projects in a phase III trial of oral rotavirus vaccine ORV | Tor Arne Strand |
| 2009 - 2012 | Integration and scaling of health information system to strengthen vaccination services delivery in india | Sundeep Sahay |
| 2009 - 2012 | A rapid serological screening method for detecting tuberculosis disease and monitoring the efficacy of new vaccines | Carol Holm-Hansen |
| 2009 - 2012 | Development of an outer membrane vesicle vaccine for Africa against serogroup A and W-135 meningococcal disease | Einar Rosenqvist |
| 2009 - 2012 | Studies to complete the phase II clinical stage of development for the peptide-based HIV-1 therapeutic vaccine candidate Vacc-4x | Maja A. Sommerfelt |
| 2008 - 2013 | Developing vaccines against diarrhea caused by Enterotoxigenic Escherichia coli and Shigella (EntVac) | Halvor Sommerfelt |
| 2008 - 2008 | Safety and Immunogenicity of Three Doses of ORV 116E Concomitantly Administered with Routine Childhood Vaccines OPV, DPT, Hib an | Tor Arne Strand |
